Dopamine agonist-based strategies in the treatment of Parkinson's disease

Neurological Sciences

Volumn 29, Issue SUPPL. 5, 2008, Pages

  Antonini, Angelo ^a   Barone, Paolo ^b  

^a PARKINSON INSTITUTE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Dopamine agonists; Dyskinesias; Levodopa; Motor fluctuations; Motor symptoms; Non motor symptoms; Parkinson's disease; Pramipexole

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; SELEGILINE;

ARTICLE; AUTONOMIC DYSFUNCTION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DYSKINESIA; EMOTIONAL DISORDER; HUMAN; MONOTHERAPY; MOOD DISORDER; MOTOR CONTROL; MOTOR DYSFUNCTION; PARKINSON DISEASE; PATIENT COMPLIANCE; PSYCHOSIS; QUALITY OF LIFE; SENSORY DYSFUNCTION; SYMPTOMATOLOGY; THERAPY EFFECT;

ALGORITHMS; ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; HUMANS; PARKINSON DISEASE;

EID: 65449145955     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-008-1049-4     Document Type: Article

References (19)

1. Quinn N, Critchley P, Marsden CD (1987) Young onset Parkinson's disease. Mov Disord 2:73-91
2. Schrag A, Ben-Shlomo Y, Brown R et al (1998) Young onset Parkinson's disease revisited - clinical features, natural history, and mortality. Mov Disord 13:885-894
3. Hristova AH (2000) Early Parkinson's disease: What is the best approach to treatment? Drugs Aging 17:165-181
4. Grosset D, Taurah L, Burn DJ et al (2007) A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry 78:465-469
5. Fahn S, Oakes D, Shoulson I et al (2004) Levodopa and the progression of Parkinson's disease. N Engl J Med 351:2498-2508
6. Antonini A (2007) Continuous dopaminergic stimulation - From theory to clinical practice. Parkinsonism Relat Disord 13[Suppl]:S24-S28
7. Kondo T (2002) Initial therapy for Parkinson's disease: Levodopa vs. dopamine receptor agonists. J Neurol 249[Suppl 2]:II25-II29
8. Suchowersky O, Reich S, Perlmutter J et al (2006) Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review) of the American Academy of Neurolology. Neurology 66:968-975
9. Rinne UK, Bracco F, Chouza C et al (1998) Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 55[Suppl 1]:23-30
10. Rascol O, Brooks DJ, Korczyn AD et al (2000) A five year study of the incidence of dyskinesia in patients with early Parkinson's disease who where treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342:1484-1491
11. The Parkinson Study Group (2002) Pramipexole vs Levodopa as initial treatment for Parkinson Disease. A randomized controlled study. JAMA 5:1653-1661
12. Antonini A, Poewe W (2007) Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 6:826-829
13. Parkinson Study Group (2002) A controlled trial of rasagiline in early Parkinson disease: The TEMPO study. Arch Neurol 59:1937-1943
14. Chaudhuri RK, Healy D, Shapira HV et al (2006) Non-motor symptoms of Parkinson's disease: Diagnosis and management. Lancet Neurol 5:235-245
15. Antonini A, Colosimo C, Marconi R et al (2008) The PRIAMO study: background, methods and recruitment. Neurol Sci 29:61-65
16. Antonini A (2008) Unravelling depression in Parkinson's disease. Eur J Neurol 15:885-886
17. Kulisevsky J, Pascual-Sedano B, Barbanoj M et al (2007) Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: A double-blind study. Mov Disord 22:62-67
18. Lemke MR, Brecht HM, Koester J, Reichmann H (2006) Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. J Neurol Sci 248:266-270
19. Barone P, Scarzella L, Marconi R et al and the Depression/Parkinson Italian Study Group (2006) Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: A national multicenter parallel-group randomized study. J Neurol 253:601-607